MAHLY (Medipal Holdings) Beta: 0.0399 (As of Jun. 25, 2026)


MAHLY Medipal Holdings Corp MAHLY
78 GF Score
Price $15.37
GF Value $15.83
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Medipal Holdings Beta?

Medipal Holdings MAHLY 78 Beta is 0.0399 as of Jun. 25, 2026. GuruFocus rates MAHLY with a GF Score™ of 78/100 and a GF Value™ of $15.83 (Fairly Valued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Medipal Holdings's Beta is 0.0399.


Medipal Holdings  (OTCPK:MAHLY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Medipal Holdings Beta Related Terms


Medipal Holdings Beta Historical Data

* Premium members only.

The historical data trend for Medipal Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medipal Holdings Beta Chart

Medipal Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.18 0.16 0.15 -0.02

Medipal Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 -0.07 -0.15 -0.28 -0.02

MAHLY vs MCK, COR, CAH: Beta Comparison

For the Medical Distribution subindustry, Medipal Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medipal Holdings Beta vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Medipal Holdings's Beta falls into.


MAHLY
78GF Score
Medipal Holdings Corp MAHLY
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medipal Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0399 mean?
Medipal Holdings (MAHLY) has a Beta of 0.0399 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medipal Holdings and its competitors.
Is Medipal Holdings' Beta too high?
Medipal Holdings' current Beta is 0.0399. Overall, Medipal Holdings has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Beta compare to MCK and COR?
Medipal Holdings' Beta of 0.0399 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Distribution company?
A good Beta depends on the Medical Distribution industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medipal Holdings and its competitors. Medipal Holdings's current Beta is 0.0399. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $15.83, compared to a current price of $15.37 — trading 2.9% below its estimated fair value. The current Beta is 0.0399. Medipal Holdings' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current Beta is 0.0399 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medipal Holdings (MAHLY) Overvalued in 2026?

Based on GuruFocus' analysis, Medipal Holdings stock appears to be undervalued. The current stock price of $15.37 is trading 2.9% below its estimated GF Value™ of $15.83. GuruFocus considers Medipal Holdings to be Fairly Valued.

Key valuation signals for MAHLY:

  • Beta: 0.0399
  • GF Value™: $15.83 vs. price of $15.37 (2.9% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medipal Holdings Business Description

Other Exchanges MEPDF:USA7459:Japan
Address 3-1-1 Kyobashi, Chuo-ku, Tokyo, JPN, 104-8461
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
78GF Score

Get the complete analysis for MAHLY

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.37
Price
$15.83
GF Value